PPL-100

PPL-100 is a protease inhibitor drug developed by Ambrilia. The drug was licensed to Merck until 2008 when it was returned to Ambrilia. It is currently in phase I trials. Earlier in vitro studies indicate it may have a high genetic barrier to resistance, low cross-resistance to other PIs, and will not require ritonavir boosting.

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.